MCID: MRG003
MIFTS: 51

Marginal Zone B-Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Marginal Zone B-Cell Lymphoma

MalaCards integrated aliases for Marginal Zone B-Cell Lymphoma:

Name: Marginal Zone B-Cell Lymphoma 38 12 14 69
Marginal Zone Lymphoma 12 50
Mucosa-Associated Lymphoid Tissue Lymphoma 69
Mzl 50

Classifications:



External Ids:

Disease Ontology 12 DOID:0050748

Summaries for Marginal Zone B-Cell Lymphoma

Disease Ontology : 12 A B-cell lymphoma that is characterized by initial formation in the marginal zones of lymph tissue.

MalaCards based summary : Marginal Zone B-Cell Lymphoma, also known as marginal zone lymphoma, is related to lymphoma, malt, somatic and splenic marginal zone lymphoma. An important gene associated with Marginal Zone B-Cell Lymphoma is BCL6 (B-Cell CLL/Lymphoma 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 72 Marginal zone lymphomas are a group of slow-growing non-Hodgkin B-cell lymphomas, which account for... more...

Related Diseases for Marginal Zone B-Cell Lymphoma

Diseases related to Marginal Zone B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
id Related Disease Score Top Affiliating Genes
1 lymphoma, malt, somatic 29.3 BCL10 BCL2 BCL6 CCND1 CD40LG CD5
2 splenic marginal zone lymphoma 12.6
3 primary cutaneous marginal zone b-cell lymphoma 12.5
4 nodal marginal zone b-cell lymphoma 12.5
5 b-cell lymphomas 11.2
6 lymphoma 11.2
7 b-cell lymphoma of mucosa-associated lymphoid tissue 10.8
8 cervical endometrioid adenocarcinoma 10.7 BCL6 CD5
9 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.6 IRF4 MYD88
10 thrombocytopenia 10.6 BCL6 MYD88
11 nuchal bleb, familial 10.6 CD40LG CD5
12 pediatric lymphoma 10.6 BCL6 CD5
13 gamma heavy chain disease 10.5 CD40LG MYD88
14 biotin-responsive multiple carboxylase deficiencies 10.5 BCL10 BCL6 MALT1
15 vaccinia 10.5 BCL2 CD5
16 glandular-alveolar pattern testicular yolk sac tumor 10.5 BCL2 CD5
17 folliculotropic mycosis fungoides 10.5 BCL10 IRF4 MALT1
18 cd40 ligand deficiency 10.5 CD40LG MALT1
19 gastric small cell carcinoma 10.5 BCL6 MME
20 colonic benign neoplasm 10.5 CD40LG MYD88
21 syngnathia cleft palate 10.5 BCL6 CD5 MALT1
22 hepatitis 10.5
23 trigeminal nerve neoplasm 10.4 CD5 MME
24 childhood spinal cord tumor 10.4 BCL6 CD5
25 embryonal rhabdomyosarcoma 10.4 BCL6 MALT1 MYD88
26 transient hypogammaglobulinemia 10.4 CD19 CD40LG
27 pseudotyphus of california 10.4 BCL2 BCL6 MALT1
28 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.4 BCL6 MME
29 thrombocytopenia, anemia, and myelofibrosis 10.4 BCL10 BCL2 BCL6
30 scrotum basal cell carcinoma 10.4 CD19 CD40LG
31 infectious anterior uveitis 10.3 CD40LG TNFAIP3
32 mohr syndrome 10.3 BCL10 MALT1
33 tang hsi ryu syndrome 10.3 BCL6 MME
34 diffuse large b-cell lymphoma 10.3
35 amyloidosis 10.3
36 histiocytosis 10.3
37 thyroiditis 10.3
38 plexosarcoma 10.3 CCND1 IRF4
39 primary malignant melanoma of the cervix 10.3 BCL2 BCL6 MYD88
40 heterotaxy, visceral, 4, autosomal 10.3 BCL2 BCL6
41 polyneuropathy due to drug 10.3 CD19 CD40LG
42 arthritis 10.2
43 plasmacytoma 10.2
44 mantle cell lymphoma 10.2
45 primary malignant melanoma of the conjunctiva 10.2 BCL6 IRF4
46 lysosomal storage disease 10.2 BCL2 CCND1
47 paraneoplastic polyneuropathy 10.2 BCL2 BCL6
48 disease_ontology 10.2 BCL2 CD40LG MYD88
49 ovarian mesodermal adenosarcoma 10.2 BCL2 MME
50 macroglobulinemia 10.2

Graphical network of the top 20 diseases related to Marginal Zone B-Cell Lymphoma:



Diseases related to Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Marginal Zone B-Cell Lymphoma

GenomeRNAi Phenotypes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.72 BCL2 CD40LG MALT1 MYD88 TNFAIP3 BCL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.72 BCL2 CD40LG MALT1 MYD88 TNFAIP3 BCL10

MGI Mouse Phenotypes related to Marginal Zone B-Cell Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CCND1 CD19 CD40LG CD5 IRF4 MALT1
2 endocrine/exocrine gland MP:0005379 9.8 BCL10 BCL2 BCL6 CCND1 CD40LG MYD88
3 immune system MP:0005387 9.73 BCL10 BCL2 BCL6 CCND1 CD19 CD40LG
4 integument MP:0010771 9.17 BCL2 CCND1 CD19 CD40LG CD5 MME

Drugs & Therapeutics for Marginal Zone B-Cell Lymphoma

Drugs for Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 486)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
3 Thiotepa Approved Phase 4,Phase 2,Phase 3 52-24-4 5453
4
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
5
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029
6
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
7
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
8
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7 4594 9579578
9 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
18 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
20
Proton pump inhibitors Phase 4,Phase 3,Phase 2
21 Antacids Phase 4,Phase 2
22 Anti-Ulcer Agents Phase 4,Phase 2
23 Antimalarials Phase 4,Phase 2,Phase 1
24
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
25
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
26
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
27
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
28
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
29
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
30
Idarubicin Approved Phase 3 58957-92-9 42890
31
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
32
Vidarabine Approved Phase 3,Phase 1,Phase 2 24356-66-9 32326 21704
33
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
34
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
35
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
36
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
37
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
38
Ofloxacin Approved Phase 3 82419-36-1 4583
39
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
40
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
41
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
42
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
43
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
44
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
45
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
46
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
47
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
48
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
49
Piperacillin Approved Phase 3 66258-76-2 43672
50
Tazobactam Approved Phase 3 89786-04-9 123630

Interventional clinical trials:

(show top 50) (show all 692)

id Name Status NCT ID Phase Drugs
1 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Not yet recruiting NCT02959255 Phase 4 Esomeprazole
4 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Not yet recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
5 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
6 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
7 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
8 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
9 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
10 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
11 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
12 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
13 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
14 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
15 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
16 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
17 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
18 A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Completed NCT02302170 Phase 3
19 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
20 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
21 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
22 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
23 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
24 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
25 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
26 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
27 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
28 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
29 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
30 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
31 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
32 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
33 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
34 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
35 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
36 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
37 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
38 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
39 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
40 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
41 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
42 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
43 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
44 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
45 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
46 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
47 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
48 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
49 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
50 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. Recruiting NCT01996865 Phase 3 Lenalidomide;Rituximab

Search NIH Clinical Center for Marginal Zone B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Marginal Zone B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Marginal Zone B-Cell Lymphoma

Anatomical Context for Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Marginal Zone B-Cell Lymphoma:

39
B Cells, Bone, Bone Marrow, T Cells, Kidney, Breast, Lung

Publications for Marginal Zone B-Cell Lymphoma

Articles related to Marginal Zone B-Cell Lymphoma:

(show top 50) (show all 408)
id Title Authors Year
1
Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa. ( 28870925 )
2017
2
Comparative gene-expression profiling of the large cell variant of gastrointestinal marginal-zone B-cell lymphoma. ( 28729720 )
2017
3
Full circle: Extranodal marginal zone B-cell lymphoma of the trachea. ( 28838381 )
2017
4
Marginal zone B-cell lymphoma mimicking extramedullary plasmacytoma and the clinical outcome after treatment. ( 28507591 )
2017
5
Change of Serum IgG4 in Patients with Ocular Adnexal Marginal Zone B Cell Lymphoma Associated with IgG4-Related Ophthalmic Disease After Treatment. ( 28514197 )
2017
6
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue with plasma cell differentiation: Periodic acid-schiff reaction-positive Dutcher body is a diagnostic clue to distinguish it from plasmacytoma. ( 28233949 )
2017
7
Extranodal marginal zone B cell lymphoma: An unexpected complication in children with SjAPgren's syndrome. ( 28284773 )
2017
8
A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. ( 28695630 )
2017
9
Primary hepatic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type: A case report and literature review. ( 28353562 )
2017
10
Low Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-cell Lymphoma. ( 28618774 )
2017
11
Characteristics of primary extranodal marginal zone B-cell lymphoma in Korea: conjunctiva versus other ocular adnexa. ( 28814410 )
2017
12
Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung. ( 28457544 )
2017
13
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). ( 28833354 )
2017
14
Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. ( 27460179 )
2016
15
Intracranial marginal zone B-cell lymphoma mimicking meningioma: case report. ( 27155383 )
2016
16
Misdiagnosis of primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type, a case report. ( 26956381 )
2016
17
Lacrimal gland extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue-type associated with massive amyloid deposition. ( 27010357 )
2016
18
Epidermotropic skin involvement of splenic marginal zone B-cell lymphoma: a diagnostic challenge. ( 28008643 )
2016
19
Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter? ( 27548082 )
2016
20
Primary Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue of the Lacrimal Sac Found with Epiphora: A Case Report. ( 27790131 )
2016
21
Paediatric primary cutaneous marginal zone B-cell lymphoma: Does it differ from the adult counterpart? ( 27501236 )
2016
22
Primary Cutaneous Marginal Zone B-Cell Lymphoma Presenting as a Small Mass on Temple Area. ( 27152562 )
2016
23
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. ( 27443419 )
2016
24
Extranodal pulmonary marginal zone B-cell lymphoma. ( 27330951 )
2016
25
Extranodal Marginal Zone B-cell Lymphoma of the Ocular Adnexa. ( 27218791 )
2016
26
Bilateral Bronchiectasis as a Presentation Form of Pulmonary Marginal Zone B-Cell Lymphoma of Bronchus Associated Lymphoid Tissue. ( 26839723 )
2015
27
MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. ( 25723115 )
2015
28
A case of contiguous primary hepatic marginal zone B-cell lymphoma and hemangioma ultimately diagnosed using contrast-enhanced ultrasonography. ( 25848352 )
2015
29
Clinicopathological Analysis of Ocular Adnexal Extranodal Marginal Zone B-Cell Lymphoma with IgG4-Positive Cells. ( 26111022 )
2015
30
Primary Cutaneous Marginal Zone B Cell Lymphoma of the Eyelid Skin: Diagnostic Clues and Distinction from Other Ocular Adnexal Disease. ( 26545575 )
2015
31
Primary extranodal marginal zone B-cell lymphoma with diffuse uveal involvement and focal infiltration of the trabecular meshwork: a case report and review of literature. ( 25947067 )
2015
32
Primary thymic extranodal marginal zone B cell lymphoma as an incidental finding in a Caucasian woman. ( 26338245 )
2015
33
Marginal zone B-cell lymphoma of the pulmonary mucosa-associated lymphoid tissue: A case report. ( 26622741 )
2015
34
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Tissue Type involving the Dura. ( 26194368 )
2015
35
A 44-year old male with right-sided facial numbness. Dura-associated extranodal marginal zone B cell lymphoma (MALT lymphoma). ( 25521183 )
2015
36
77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). ( 25521182 )
2015
37
Conjunctival extranodal marginal zone B-cell lymphoma with crystal-storing histiocytosis. ( 25988528 )
2015
38
A case of marginal zone B cell lymphoma mimicking IgG4-related dacryoadenitis and sialoadenitis. ( 25889621 )
2015
39
Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. ( 25338969 )
2014
40
Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C. ( 25024777 )
2014
41
Acquired angioedema with C1 inhibitor deficiency secondary to splenic marginal zone B-cell lymphoma. ( 24970460 )
2014
42
Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). ( 23925930 )
2014
43
Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas. ( 25320370 )
2014
44
A rare case of splenic marginal zone B-cell lymphoma mimicking relapsing polychondritis of the ear. ( 25544924 )
2014
45
IgG4-related dacryoadenitis evolving into an extra-nodal, marginal zone B-cell lymphoma (EMZL): a tale of two lacrimal glands. ( 24977741 )
2014
46
Cutaneous Marginal Zone B-cell Lymphoma Evolving into Anetoderma: A Role of Matrix Metalloproteinases? ( 25350822 )
2014
47
PD-1, S-100, and CD1a Expression in Pseudolymphomatous Folliculitis, Primary Cutaneous Marginal Zone B-cell Lymphoma (MALT lymphoma), and Cutaneous Lymphoid Hyperplasia. ( 25384543 )
2014
48
Extranodal marginal zone B-cell lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma) in ulcerative colitis. ( 25253369 )
2014
49
Crystal-storing histiocytosis complicating marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. ( 25216699 )
2014
50
Extranodal marginal zone B cell lymphoma of the orbit in a patient with sarcoidosis: a case report. ( 25363228 )
2014

Variations for Marginal Zone B-Cell Lymphoma

Cosmic variations for Marginal Zone B-Cell Lymphoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM85942 MYD88 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,marginal zone lymphoma c.695T>C p.M232T 3
2 COSM85940 MYD88 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,marginal zone lymphoma c.794T>C p.L265P 3

Expression for Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Marginal Zone B-Cell Lymphoma.

Pathways for Marginal Zone B-Cell Lymphoma

Pathways related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 BCL10 BCL2 BCL6 C1S CCND1 CD19
2
Show member pathways
13.18 BCL2 BCL6 CCND1 CD40LG IRF4 MYD88
3
Show member pathways
13.01 BCL10 BCL2 CCND1 CD19 MALT1 MYD88
4
Show member pathways
12.8 BCL10 BCL2 MALT1 MYD88 TNFAIP3
5
Show member pathways
12.47 BCL10 CD40LG MALT1 MYD88 TNFAIP3
6
Show member pathways
12.43 BCL2 CD40LG MYD88 TNFAIP3
7
Show member pathways
12.25 BCL10 CD40LG IRF4 MALT1
8
Show member pathways
12.14 BCL10 BCL6 CD19 IRF4 MALT1
9 12.03 BCL10 BCL2 MALT1 MYD88
10 11.98 BCL10 BCL2 CD40LG MALT1 TNFAIP3
11 11.83 CD19 CD5 MME
12 11.81 BCL2 BCL6 CCND1
13 11.79 BCL2 BCL6 CCND1 IRF4
14 11.72 CD19 CD5 MME
15 11.72 BCL10 BCL6 CD19 CD40LG IRF4 MALT1
16 11.58 CD19 IRF4 MME
17 11.54 MALT1 MYD88 TNFAIP3
18 11.47 BCL6 CD40LG IRF4
19 11.41 BCL10 BCL2 CD40LG MALT1 MYD88 TNFAIP3
20 11.28 BCL6 CD19 CD40LG CD5 MME
21 10.94 BCL10 MALT1 TNFAIP3

GO Terms for Marginal Zone B-Cell Lymphoma

Cellular components related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.35 BCL10 BCL2 CD19 MALT1 MYD88
2 CBM complex GO:0032449 8.62 BCL10 MALT1

Biological processes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.86 BCL10 BCL6 C1S MYD88
2 inflammatory response GO:0006954 9.84 BCL6 CD40LG MYD88 TNFAIP3
3 negative regulation of apoptotic process GO:0043066 9.83 BCL2 BCL6 CD40LG MALT1 MYD88
4 regulation of apoptotic process GO:0042981 9.8 BCL10 BCL2 BCL6 MALT1
5 protein oligomerization GO:0051259 9.65 BCL10 MALT1 TNFAIP3
6 regulation of inflammatory response GO:0050727 9.63 BCL6 MYD88 TNFAIP3
7 B cell differentiation GO:0030183 9.58 BCL2 BCL6 CD40LG
8 positive regulation of T cell activation GO:0050870 9.55 BCL10 MALT1
9 response to iron ion GO:0010039 9.52 BCL2 CCND1
10 immunoglobulin mediated immune response GO:0016064 9.51 BCL10 MYD88
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.46 BCL10 MALT1 MYD88 SLC35B2
12 response to fungus GO:0009620 9.37 BCL10 MALT1
13 regulation of T cell receptor signaling pathway GO:0050856 9.32 BCL10 MALT1
14 regulation of germinal center formation GO:0002634 9.26 BCL6 TNFAIP3
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.26 BCL10 CD40LG MALT1 MYD88
16 response to molecule of bacterial origin GO:0002237 8.8 BCL10 MALT1 TNFAIP3

Molecular functions related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 BCL10 BCL2 BCL6 C1S MYD88 TNFAIP3
2 transcription factor binding GO:0008134 9.62 BCL10 BCL2 CCND1 IRF4
3 kinase activator activity GO:0019209 9.26 BCL10 MALT1
4 protease binding GO:0002020 9.26 BCL10 BCL2 MALT1 TNFAIP3
5 protein self-association GO:0043621 8.92 BCL10 MALT1 MYD88 TNFAIP3
6 protein binding GO:0005515 10.18 BCL10 BCL2 BCL6 C1S CCND1 CD19

Sources for Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....